Coronavirus 2019 disease : are corticosteroids the key treatment? : a retrospective case-control study in Brazil
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UnB |
Texto Completo: | http://repositorio2.unb.br/jspui/handle/10482/46045 https://doi.org/10.1016/j.amsu.2022.104746 https://orcid.org/0000-0003-2798-3564 |
Resumo: | Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is the putative cause of coronavirus disease 2019 (COVID-19), a serious disease that has severely impacted the world. Although vaccines have been developed, it will take time to inoculate the global population. Current guidelines have focused on the treatment of severe cases in hospital settings; however, a void has been created regarding appropriate measures for those in the initial stage of COVID-19 and those experiencing moderate disease severity progressing to desaturation. We assessed clinical outcomes in patients with COVID-19 with pneumonia at initial presentation treated with corticosteroids. Methods: Data of 177 consecutive high-risk patients with COVID-19, monitored by telemedicine, were collected and analyzed. Of those, 68 patients were in the initial inflammatory phase of the disease without desaturation and received corticosteroids. The outcomes were evaluated after a follow up of 14 days. Four patients were immediately referred to the hospital because they had explicit desaturation at presentation. Results: After 14 days, all patients in the inflammatory phase at presentation who were treated with corticosteroids before desaturation were alive and without complications. However, of the four patients with desaturation, one died at the hospital. Conclusion: In this study, the use of corticosteroids during the initial pulmonary phase of COVID-19 before desaturation, in addition to daily monitoring of patients, prevented disease progression, decreased the risk of complications and incidence of hospitalization and death. However, additional studies with larger number of patients are needed to confirm these findings. |
id |
UNB_4d8bf75b53ed8cc6b4fc8231cac1afa8 |
---|---|
oai_identifier_str |
oai:repositorio.unb.br:10482/46045 |
network_acronym_str |
UNB |
network_name_str |
Repositório Institucional da UnB |
repository_id_str |
|
spelling |
Coronavirus 2019 disease : are corticosteroids the key treatment? : a retrospective case-control study in BrazilCovid-19CorticóideBackground: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is the putative cause of coronavirus disease 2019 (COVID-19), a serious disease that has severely impacted the world. Although vaccines have been developed, it will take time to inoculate the global population. Current guidelines have focused on the treatment of severe cases in hospital settings; however, a void has been created regarding appropriate measures for those in the initial stage of COVID-19 and those experiencing moderate disease severity progressing to desaturation. We assessed clinical outcomes in patients with COVID-19 with pneumonia at initial presentation treated with corticosteroids. Methods: Data of 177 consecutive high-risk patients with COVID-19, monitored by telemedicine, were collected and analyzed. Of those, 68 patients were in the initial inflammatory phase of the disease without desaturation and received corticosteroids. The outcomes were evaluated after a follow up of 14 days. Four patients were immediately referred to the hospital because they had explicit desaturation at presentation. Results: After 14 days, all patients in the inflammatory phase at presentation who were treated with corticosteroids before desaturation were alive and without complications. However, of the four patients with desaturation, one died at the hospital. Conclusion: In this study, the use of corticosteroids during the initial pulmonary phase of COVID-19 before desaturation, in addition to daily monitoring of patients, prevented disease progression, decreased the risk of complications and incidence of hospitalization and death. However, additional studies with larger number of patients are needed to confirm these findings.Faculdade de Medicina (FMD)Elsevier Ltd on behalf of IJS Publishing Group Ltd.University of Brasília, School of MedicineUniversity of Brasília, School of MedicineUniversity of Brasília, School of MedicineUniversity of Brasília, School of MedicineFederal University of São Paulo, Department of Obstetrics Paulista School of MedicineMunicipal Universidade of São Caetano Do Sul, Medical Course, Bela Vista CampusRios, Salete da SilvaChen, Ana Carolina RiosChen, Juliana RiosResende, Ceres Nunes deAraujo Júnior, Edward2023-07-10T15:00:46Z2023-07-10T15:00:46Z2022info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfRIOS,Salete S. et al. Coronavirus 2019 disease: are corticosteroids the key treatment?: a retrospective case-control study in Brazil. Annals of Medicine and Surgery, [S.l.], v. 82, 104746, 2022. DOI: https://doi.org/10.1016/j.amsu.2022.104746. Disponível em: https://www.sciencedirect.com/science/article/pii/S2049080122015060. Acesso em 08 jul. 2023.http://repositorio2.unb.br/jspui/handle/10482/46045https://doi.org/10.1016/j.amsu.2022.104746https://orcid.org/0000-0003-2798-3564eng© 2022 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).info:eu-repo/semantics/openAccessreponame:Repositório Institucional da UnBinstname:Universidade de Brasília (UnB)instacron:UNB2023-07-10T15:00:47Zoai:repositorio.unb.br:10482/46045Repositório InstitucionalPUBhttps://repositorio.unb.br/oai/requestrepositorio@unb.bropendoar:2023-07-10T15:00:47Repositório Institucional da UnB - Universidade de Brasília (UnB)false |
dc.title.none.fl_str_mv |
Coronavirus 2019 disease : are corticosteroids the key treatment? : a retrospective case-control study in Brazil |
title |
Coronavirus 2019 disease : are corticosteroids the key treatment? : a retrospective case-control study in Brazil |
spellingShingle |
Coronavirus 2019 disease : are corticosteroids the key treatment? : a retrospective case-control study in Brazil Rios, Salete da Silva Covid-19 Corticóide |
title_short |
Coronavirus 2019 disease : are corticosteroids the key treatment? : a retrospective case-control study in Brazil |
title_full |
Coronavirus 2019 disease : are corticosteroids the key treatment? : a retrospective case-control study in Brazil |
title_fullStr |
Coronavirus 2019 disease : are corticosteroids the key treatment? : a retrospective case-control study in Brazil |
title_full_unstemmed |
Coronavirus 2019 disease : are corticosteroids the key treatment? : a retrospective case-control study in Brazil |
title_sort |
Coronavirus 2019 disease : are corticosteroids the key treatment? : a retrospective case-control study in Brazil |
author |
Rios, Salete da Silva |
author_facet |
Rios, Salete da Silva Chen, Ana Carolina Rios Chen, Juliana Rios Resende, Ceres Nunes de Araujo Júnior, Edward |
author_role |
author |
author2 |
Chen, Ana Carolina Rios Chen, Juliana Rios Resende, Ceres Nunes de Araujo Júnior, Edward |
author2_role |
author author author author |
dc.contributor.none.fl_str_mv |
University of Brasília, School of Medicine University of Brasília, School of Medicine University of Brasília, School of Medicine University of Brasília, School of Medicine Federal University of São Paulo, Department of Obstetrics Paulista School of Medicine Municipal Universidade of São Caetano Do Sul, Medical Course, Bela Vista Campus |
dc.contributor.author.fl_str_mv |
Rios, Salete da Silva Chen, Ana Carolina Rios Chen, Juliana Rios Resende, Ceres Nunes de Araujo Júnior, Edward |
dc.subject.por.fl_str_mv |
Covid-19 Corticóide |
topic |
Covid-19 Corticóide |
description |
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is the putative cause of coronavirus disease 2019 (COVID-19), a serious disease that has severely impacted the world. Although vaccines have been developed, it will take time to inoculate the global population. Current guidelines have focused on the treatment of severe cases in hospital settings; however, a void has been created regarding appropriate measures for those in the initial stage of COVID-19 and those experiencing moderate disease severity progressing to desaturation. We assessed clinical outcomes in patients with COVID-19 with pneumonia at initial presentation treated with corticosteroids. Methods: Data of 177 consecutive high-risk patients with COVID-19, monitored by telemedicine, were collected and analyzed. Of those, 68 patients were in the initial inflammatory phase of the disease without desaturation and received corticosteroids. The outcomes were evaluated after a follow up of 14 days. Four patients were immediately referred to the hospital because they had explicit desaturation at presentation. Results: After 14 days, all patients in the inflammatory phase at presentation who were treated with corticosteroids before desaturation were alive and without complications. However, of the four patients with desaturation, one died at the hospital. Conclusion: In this study, the use of corticosteroids during the initial pulmonary phase of COVID-19 before desaturation, in addition to daily monitoring of patients, prevented disease progression, decreased the risk of complications and incidence of hospitalization and death. However, additional studies with larger number of patients are needed to confirm these findings. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022 2023-07-10T15:00:46Z 2023-07-10T15:00:46Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
RIOS,Salete S. et al. Coronavirus 2019 disease: are corticosteroids the key treatment?: a retrospective case-control study in Brazil. Annals of Medicine and Surgery, [S.l.], v. 82, 104746, 2022. DOI: https://doi.org/10.1016/j.amsu.2022.104746. Disponível em: https://www.sciencedirect.com/science/article/pii/S2049080122015060. Acesso em 08 jul. 2023. http://repositorio2.unb.br/jspui/handle/10482/46045 https://doi.org/10.1016/j.amsu.2022.104746 https://orcid.org/0000-0003-2798-3564 |
identifier_str_mv |
RIOS,Salete S. et al. Coronavirus 2019 disease: are corticosteroids the key treatment?: a retrospective case-control study in Brazil. Annals of Medicine and Surgery, [S.l.], v. 82, 104746, 2022. DOI: https://doi.org/10.1016/j.amsu.2022.104746. Disponível em: https://www.sciencedirect.com/science/article/pii/S2049080122015060. Acesso em 08 jul. 2023. |
url |
http://repositorio2.unb.br/jspui/handle/10482/46045 https://doi.org/10.1016/j.amsu.2022.104746 https://orcid.org/0000-0003-2798-3564 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier Ltd on behalf of IJS Publishing Group Ltd. |
publisher.none.fl_str_mv |
Elsevier Ltd on behalf of IJS Publishing Group Ltd. |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UnB instname:Universidade de Brasília (UnB) instacron:UNB |
instname_str |
Universidade de Brasília (UnB) |
instacron_str |
UNB |
institution |
UNB |
reponame_str |
Repositório Institucional da UnB |
collection |
Repositório Institucional da UnB |
repository.name.fl_str_mv |
Repositório Institucional da UnB - Universidade de Brasília (UnB) |
repository.mail.fl_str_mv |
repositorio@unb.br |
_version_ |
1810580708079435776 |